FDA to Review Omalizumab for Chronic Rhinosinusitis With Nasal Polyps
The FDA has accepted for filing the sBLA for omalizumab for the treatment of adults with chronic rhinosinusitis with nasal polyps who have had an inadequate response to intranasal corticosteroids.
